Ianalumab+standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia

Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or needing another treatment for their ITP,…

Continue Reading

News Source: medicalxpress.com